AI Article Synopsis

  • New dual-responsive nanocarriers were created using bimetallic Au-Ag nanoparticles to enhance targeted cancer therapy by integrating both chemo and photothermal effects.
  • The system utilizes localized heating to trigger drug release while also increasing temperatures to eliminate cancer cells, achieving temperature increases of nearly 18°C within 5 minutes of laser exposure.
  • The nanocarriers demonstrated excellent reusability after several heating/cooling cycles, and their drug delivery effectiveness can be adjusted by altering carrier concentration and radiation duration.

Article Abstract

New dual light/temperature-responsive nanocarriers were synthesized using bimetallic plasmonic Au-Ag and Ag-Au nanoparticles (NPs) as cores of vehicles which subsequently functionalized with an upper critical solubility temperature-based poly acrylamide-co-acrylonitrile using reversible addition-fragmentation chain transfer for spatiotemporally controlled chemo-photothermal synergistic cancer therapy. The bimetallic cores were assigned to sense wavelengths close to the localized surface plasmon resonance of monometallic NP shell to produce heat which not only can increase the surrounding temperature over the upper critical solubility temperature of polymer to open its valves and promote drug diffusion but also can kill cancerous cells through photothermal effects with increase in environment temperature by nearly 18°C after about 5 min radiation. The bimetallic NPs were shown good reusability even after 5 heating/cooling cycles, and the efficiency of both photothermal/chemotherapic procedures can be modulated by manipulating carrier's concentration and radiation time. In addition, the cytotoxicity of drug-free nanocarriers on normal L929 fibroblast and letrozole-loaded nanocarriers on MDAMB 231 breast-cancer cell lines were investigated in the absence/presence of laser radiation. Finally, the prepared nanocomposites were exhibited switchable on/off drug release in 2 buffered solutions (pH 5.5 and 7.4) with light actuation. The results revealed that the prepared nanocarriers can be served as efficient delivery platforms for remote-control chemophotothermal synergistic cancer therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.xphs.2018.05.025DOI Listing

Publication Analysis

Top Keywords

synergistic cancer
12
cancer therapy
12
surface plasmon
8
chemo-photothermal synergistic
8
upper critical
8
critical solubility
8
tunable surface
4
plasmon resonance-based
4
resonance-based remote
4
remote actuation
4

Similar Publications

Metastasis continues to pose a significant challenge in tumor treatment. Evidence indicates that choline dehydrogenase (CHDH) is crucial in tumorigenesis. However, the functional role of CHDH in colorectal cancer (CRC) metastasis remains unreported.

View Article and Find Full Text PDF

Carrier-Free, Hyaluronic Acid-Modified Self-Assembled Doxorubicin, and Chlorin e6 Nanoparticles Enhance Combined Chemo- and Photodynamic Therapy in vivo.

Int J Nanomedicine

January 2025

State Key Laboratory of Ophthalmology, Optometry and Visual Science, National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China.

Background: Developing carrier-free nanomedicines via self-assembly of two antitumor drug molecules is a potential strategy for enhancing the combination treatment of tumors. Similarly, conventional chemotherapy combined with photodynamic therapy may synergistically improve the antitumor effect while minimizing the adverse reactions associated with antitumor treatment. Hyaluronic acid (HA) can bind to overexpressed HA receptors on the tumor cell surface, increasing cell internalization and resulting in good tumor-targeting properties.

View Article and Find Full Text PDF

Immune Checkpoint Inhibitor Combined with Antiangiogenic Agent Synergistically Improving the Treatment Efficacy for Solid Tumors.

Immunotargets Ther

December 2024

Department of Thoracic Surgery, Nanjing Drum Tower Hospital, Medical School of Nanjing University, Nanjing, 210008, People's Republic of China.

In recent years, the combination of immune checkpoint inhibitors (ICIs) with antiangiogenic agents has led to significant breakthroughs in cancer treatment. Such as programmed cell death 1 (PD-1), programmed cell death ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Antiangiogenic therapy plays a pivotal role in normalizing blood vessels and remodeling the tumor immune microenvironment while ICIs not only enhance the host's antitumor immune response by blocking negative regulatory signals but also promote vascular normalization.

View Article and Find Full Text PDF

Background: Targeted therapies, including axitinib, a vascular endothelial growth factor receptor inhibitor, and sintilimab, a programmed cell death protein-1 inhibitor, have shown promise in the treatment of advanced renal cell carcinoma (RCC). Although their individual efficacies have been demonstrated, the potential synergistic effects of combining these two agents are still being explored.

Methods: This study retrospectively analysed patients with advanced RCC admitted to our hospital from January 2022 to December 2023.

View Article and Find Full Text PDF

Glucose oxidase (GOX)-induced starvation is a safe treatment for tumor. However, the non-specific targeting of GOX and the plasticity of tumor metabolism lead to toxic side effects and low tumor mortality. Thus, it is necessary to develop a synergistic strategy with high tumor targeting specificity to enhance the mortality of GOX.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!